UTHealth is one of eight U.S. sites for the trial. Photo via uth.edu

Aided by technology, medical sleuths at the University of Texas Health Science Center at Houston are tracking the long-term effects of COVID-19 as part of a national study.

At the heart of the study is an app that allows patients who have shown COVID-19 symptoms and have been tested for COVID-19 to voluntarily share their electronic health records with researchers. The researchers then can monitor long-term symptoms like brain fog, fatigue, depression, and cardiovascular problems.

UTHealth is one of eight U.S. sites for the INSPIRE trial (Innovative Support for Patients with SARS COV-2 Infections Registry). Researchers are recruiting study participants from Memorial Hermann-Texas Medical Center. They want to expand recruitment to urgent care clinics in the Houston area.

Aside from accessing patients' data through the Hugo Health platform, UTHealth researchers will ask participants to fill out brief follow-up surveys every three months over the course of 18 months. The study complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), the federal law that protects patients' information from being disclosed without their knowledge.

"This is a very novel and important study," Dr. Ryan Huebinger, assistant professor in the Department of Emergency Medicine at UTHealth's McGovern Medical School and co-principal investigator of the study, says in a news release.

In a study like this, researchers typically must see a patient in person or at least reach out to them.

"Using this platform is novel because we don't have to schedule additional appointments or ask questions like 'How long were you hospitalized?' – we can automatically see that in their records and survey submissions," Huebinger says.

Mandy Hill, associate professor in the McGovern Medical School's Department of Emergency Medicine and the study's co-principal investigator, says about one-fourth of the people in the study will be local residents who didn't test positive for COVID-19.

"That group will be our control group to be able to compare things like prevalence and risk factors," Huebinger says.

Eligible participants must be at least 18 years old, must have experienced COVID-19 symptoms, and must have been tested for COVID-19 in the past four weeks.

"This is not going to be the last pandemic. The more information we can gather across communities now will give us a leg up when the next pandemic happens," Hill says, "so that we can be more prepared to take steps toward prevention."

Researchers hope to sign up at least 300 study participants in Houston. The entire INSPIRE trial seeks to enroll 4,800 participants nationwide. The study is supposed to end in November 2022.

"There's such great potential for numerous research findings to come out of this study. We could find out if people in Houston are suffering from post-COVID-19 symptoms differently than other parts of the country, whether minorities are more affected by long-hauler symptoms, and if certain interventions work better than others," Hill says.

The U.S. Centers for Disease Control and Prevention (CDC) is financing the study. Aside from UTHealth, academic institutions involved in the research are:

  • University of Texas Southwestern Medical Center in Dallas
  • Rush University Medical Center in Chicago
  • Yale University in New Haven, Connecticut
  • University of Washington in Seattle
  • Thomas Jefferson University in Philadelphia
  • University of California, Los Angeles
  • University of California, San Francisco
From biomolecular research to oral cancer immunotherapy, here are three research projects to watch out for in Houston. Photo via Getty Images

These 3 Houston researchers are revolutionizing health science innovation

research roundup

Research, perhaps now more than ever, is crucial to expanding and growing innovation in Houston — and it's happening across the city right under our noses.

In InnovationMap's latest roundup of research news, a couple local scientists are honored by awards while another duo of specialists tackle a new project.

University of Houston professor recognized with award

Mehmet Orman of UH has been selected to receive an award for his research on persister cells. Photo via UH.edu

Mehmet Orman, assistant professor of chemical and biomolecular engineering at the University of Houston Cullen College of Engineering has been honored with a Faculty Early Career Development Award from the National Science Foundation. The award comes with a $500,000 grant to study persister cells — cells that go dormant and then become tolerant to extraordinary levels of antibiotics.

"Nearly all bacterial cultures contain a small population of persister cells," says Orman in a news release. "Persisters are thought to be responsible for recurring chronic infections such as those of the urinary tract and for creating drug-resistant mutants."

Previously, Orman developed the first methods to directly measure the metabolism of persister cells. He also developed cell sorting strategies to segregate persisters from highly heterogeneous bacterial cell populations, and, according to the release, he will be using his methods in the NSF research project.

Houston researchers collaborate on oral cancer innovation

Dr. Simon Young of UTHealth and Jeffrey Hartgerink of Rice University are working on a new use for an innovative gel they developed. Photo via Rice.edu

Two Houston researchers — chemist and bioengineer Jeffrey Hartgerink at Rice University and Dr. Simon Young at the University of Texas Health Science Center at Houston — have again teamed up to advance their previous development of a sophisticated hydrogel called STINGel. This time, they are using it to destroy oral cancer tumors.

SynerGel combines a pair of antitumor agents into a gel that can be injected directly into tumors. Once there, the gel controls the release of its cargo to not only trigger cells' immune response but also to remove other suppressive immune cells from the tumor's microenvironment. The duo reported on the technology in the American Chemical Society journal ACS Biomaterials Science & Engineering.

SynerGel, combines a pair of antitumor agents into a gel that can be injected directly into tumors, where they not only control the release of the drugs but also remove suppressive immune cells from the tumor's microenvironment.

"We are really excited about this new material," Hartgerink says in a news release. "SynerGel is formulated from a specially synthesized peptide which itself acts as an enzyme inhibitor, but it also assembles into a nanofibrous gel that can entrap and release other drugs in a controlled fashion.

In 2018, the pair published research on the use of a multidomain peptide gel — the original STINGel — to deliver ADU-S100, an immunotherapy drug from a class of "stimulator of interferon gene (STING) agonists."

The research is supported by the Oral and Maxillofacial Surgery Foundation, the National Institutes of Health, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.

Texas Heart Institute researcher honored by national organization

Dr. James Martin of Texas Heart Institute has been named a senior member of the National Academy of Inventors. Photo courtesy of THI

The National Academy of Inventors have named Houston-based Texas Heart Institute's Dr. James Martin, director of the Cardiomyocyte Renewal Lab, a senior member.

Martin is an internationally recognized developmental and regenerative biologist and his research is focused on understanding how signaling pathways are related to development and tissue regeneration.

"Dr. Martin has long been a steward of scientific advancement and has proven to be a tremendous asset to the Texas Heart Institute and to its Cardiomyocyte Renewal Lab through his efforts to translate fundamental biological discoveries in cardiac development and disease into novel treatment strategies for cardiac regeneration," says Dr. Darren Woodside, vice president for research at THI, in a news release. "Everyone at the Texas Heart Institute is thrilled for Dr. Martin, whose induction into the NAI as a Senior Member is well-deserved."

Martin has authored over 170 peer-reviewed papers in top journals he holds nine U.S. patents and applications, including one provisional application, all of which have been licensed to Yap Therapeutics, a company he co-founded.

The full list of incoming NAI Senior Members, which includes three professionals from the University of Houston, is available on the NAI website.

Houston-based Pulmotect announced a grant from the U.S. Department of Defense that will fund two COVID-19 drug trials. Photo via Getty Images

Houston biotech receives up to $6M federal grant for COVID-19 treatment

DOD delivered

The Pentagon is putting its financial power behind two COVID-19 clinical trials led by Houston-based biotech company Pulmotect Inc.

The U.S. Department of Defense is pumping as much as $6 million into the pair of Phase 2 trials, which involve a total of 300 U.S. participants, according to a January 27 news release from Pulmotect. When it's inhaled, Pulmotect's drug, PUL-042, stimulates the lungs' immune system to fight bacteria, viruses, or fungi that cause respiratory illnesses.

Pulmotect joins a number of Houston organizations that have tapped into Department of Defense funding for research into COVID-19 therapies.

In January, for instance, researchers at the University of Texas Health Science Center at Houston (UTHealth) collected $5.1 million from the department to evaluate whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients.

"It's wonderful that we have COVID-19 vaccinations available now, but they won't directly help patients who are already sick in the hospital or who will become sick in the future," Dr. Holger Eltzschig, chairman of Department of Anesthesiology at UTHealth's McGovern Medical School, says in a news release.

Also in January, Houston-based clinical research organization Pharm-Olam LLC sealed a $36.3 million deal with the Department of Defense to conduct a clinical trial of an antibody treatment for inflammatory problems associated with COVID-19.

So far, Pulmotect's PUL-042 has shown promise in battling the coronaviruses that trigger MERS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome). The current trials related to the coronavirus that causes COVID-19 are evaluating PUL-042's effect on prevention of infections and reducing the severity of the disease.

Pulmotect initially designed PUL-042 to treat and prevent respiratory complications in cancer patients. But once the coronavirus pandemic set in, the company pivoted to testing the effectiveness of its drug in combatting the virus that causes COVID-19. Last May, the U.S. Food and Drug Administration (FDA) approved Pulmotect's COVID-19 trials.

Pulmotect says PUL-042 someday could be a therapy that's deployed during pandemics, epidemics, and bioterrorism attacks.

Invented at Houston's MD Anderson Cancer Center and at Texas A&M University, PUL-042 has earned patents in 10 countries. The National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and other organizations have supported R&D for PUL-042.

Founded in 2007, Pulmotect emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector. In September 2019, the company brought aboard Dr. Colin Broom as CEO. He previously was CEO of an Irish biopharmaceutical company.

Thus far, Pulmotect has garnered about $18 million in equity and about $20 million in other funding.

Before the pandemic, Pulmotect was evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by heading off complications and hospitalizations, which usually result from COPD problems caused by a bacterial or viral infection. In this context, the drug is meant to treat cancer patients undergoing chemotherapy whose weakened immune systems make them susceptible to pneumonia.

COVID-19-related stories topped this year's health tech trending articles on InnovationMap. Photo via Getty Images

Here are Houston's top 5 health innovation stories of the year

2020 in review

Editor's note: As 2020 comes to a close, InnovationMap is looking back at the year's top stories in Houston innovation. The medical world has had a busy year amid the pandemic, and health tech innovation has never been more important. InnovationMap's top stories of the year included a new academic psychiatric hospital, Houston-based COVID-19 innovations, and more.

These 7 Houston health tech companies are providing COVID-19 solutions

These Houston startups have created health care-related solutions amid the coronavirus outbreak. Getty Images

It's all hands on deck in Houston in the battle against coronavirus — and local biotech startups have risen to the occasion.

From mental health solutions and online portals to virtual medicine and new treatments, these Houston companies have recently launched or pivoted to new options in health care. Click here to continue reading.

Houston to be home to the largest academic psychiatric hospital in the country

The UTHealth Behavioral Sciences Center, set to open next year, will be unlike anything in Houston. Rendering courtesy of Perkins and Will

Film and TV portrayals of psychiatric hospitals have driven a narrative based in cold, clinical rooms and unwelcoming corridors. That picture couldn't be more inaccurate when it comes to Houston's first public mental health hospital in more than three decades. Breaking stigmas and setting a new bar for design, the UTHealth Behavioral Sciences Center is set to open its doors in late 2021.

UTHealth has brought on architecture firm Perkins and Will to design the upcoming mental health facility. The behavioral health campus will be the largest facility of its kind in the United States, becoming a place to train future physicians and specialists. Located near Texas Medical Center, the space will consist of two buildings connected by a glazed bridge, surrounded by a tranquil green space.

The 220,000-square-foot facility includes 264 new inpatient beds and will provide access to mental healthcare, substance use intervention and treatment, and medical care via integrated treatment programs. Click here to continue reading.

Photos: Houston Methodist opens new hub to showcase health tech of the future

The Center for Innovation at Houston Methodist has opened its new Technology Hub to showcase its efforts to advance digital health. Natalie Harms/InnovationMap

Houston Methodist is regularly exploring new digital health technologies, but, until recently, lacked a proper space to demonstrate their vision for the future of health care. Now, with the Center for Innovation's Technology Hub, the hospital has just that.

The tech hub opened earlier this month in Houston Methodist Hospital in the Texas Medical Center. The 3,500-square-foot tech testing ground was renovated from an 18-room patient wing and showcases new digital health technologies like virtual reality, ambient listening, wearables, voice control, and more.

"Basically this space is like a laboratory for digital health innovations," says Josh Sol, administrative director of Innovation and Ambulatory Clinical Systems at Houston Methodist. "It's an opportunity to bring doctors, administrators, and subject matter experts to talk through what digital health could be at Houston Methodist."

The tech hub has re-imagined the experiences patients have and demonstrated the effect technology can have in various experiences — from the waiting room or outpatient care to at-home health and a voice control-optimized patient room. There's a virtual reality demo room that showcases the hospital's use of VR for distraction therapy, as well as for a doctor to demonstrate a surgical procedure for his or her patient. Click here to continue reading.

Houston organization names 10 most promising life sciences startups

Here's which life science companies — in Houston and beyond — are ones to watch. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Last week, the Rice Alliance for Technology and Entrepreneurship gathered over 1,000 life science experts and attendees virtually for thought leadership as well as 40 company presentations.

The three-day 2020 Virtual Texas Life Science Forum was made possible through a partnership with BioHouston and support from Texas Medical Center and Insperity. At the close of the summit, several companies were recognized with awards.

Houston-based Starling Medical won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The digital health device company is revolutionizing severe bladder dysfunction management with artificial intelligence.

Every year at the forum, the Rice Alliance names its 10 most promising companies working on developing innovative solutions in medical devices, digital health, diagnostics, pharmaceuticals, and therapeutics. This year, Brad Burke, managing director of the Rice Alliance, says they had more applications to present than ever before. Additionally, the presenting companies — about half of which are Houston-based — have already raised more than $275 million in funding. Click here to continue reading.

Houston biotech company is creating a drug that could fight the coronavirus

Pulmotect, a clinical-stage biotechnology company based in Houston, is testing a drug that could be useful in mitigating the threats of the coronavirus, which is currently been recognized as a global health emergency. Getty Images

A drug being developed by a Houston biopharmaceutical company eventually could help combat what the World Health Organization has proclaimed a global health emergency.

Experiments conducted by clinical-stage biotechnology company Pulmotect Inc. show its PUL-042 inhaled drug has proven effective in protecting mice against two types of coronavirus: severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). Researchers performed those tests at the University of Texas Medical Branch at Galveston.

In the Galveston experiments, a single inhaled dose of PUL-042 protected lab mice from the SARS virus, and it greatly reduced the amount of virus in their lungs after the mice became infected with SARS or MERS.

"With the risks of virulent coronaviruses and other threats increasing, as shown by the recent outbreak in Wuhan that has already spread from China to other countries including the United States, Pulmotect is optimistic that its immune-stimulating technology could be useful in mitigating the threats of current and emerging pathogens and protecting vulnerable populations," says CEO Dr. Colin Broom in a news release. Click here to continue reading.

Houston-area researchers are innovating health and wellness solutions every day — even focusing on non-pandemic-related issues. Photo via Getty Images

3 research innovations in health care to know about in Houston

Research roundup

Researchers across the world are coming up with innovative breakthroughs regarding the coronavirus, but Houston research institutions are also making health and wellness discoveries outside of COVID-19.

Here are three research innovations from Houston scientists from a new cardiac medical device to artificial intelligence-driven predictive technology for cirrhosis patients.

University of Houston's new implantable cardiac device

A UH researcher has designed a flexible device that can collect key information on the human heart. Photo via UH.edu

Cardiac implants and devices like pacemakers are either made with rigid materials that don't do the moving, beating heart any favors or the devices are made with soft materials but sacrifice the quality of information collected.

Researchers led by Cunjiang Yu, a University of Houston professor of mechanical engineering, have reported in Nature Electronics a new rubbery patch designed to collect electrophysiological activity, temperature, heartbeat and other indicators, while being flexible against the heart.

Yu, who is also a principal investigator with the Texas Center for Superconductivity at UH, is the author of the paper says it's the first time a device has both been flexible and accurate. The device, which generates energy from heart beats and doesn't need an external power source, can both collect information from multiple locations on the heart — also known as spatiotemporal mapping — but it can also offer therapeutic benefits such as electrical pacing and thermal ablation, according to the researchers.

"Unlike bioelectronics primarily based on rigid materials with mechanical structures that are stretchable on the macroscopic level, constructing bioelectronics out of materials with moduli matching those of the biological tissues suggests a promising route towards next-generational bioelectronics and biosensors that do not have a hard–soft interface for the heart and other organs," the researchers wrote. "Our rubbery epicardial patch is capable of multiplexed ECG mapping, strain and temperature sensing, electrical pacing, thermal ablation and energy harvesting functions."

Yu has worked on the development of fully rubbery electronics with sensing and other biological capabilities, including for use in robotic hands, skins and other devices.

Baylor College of Medicine's new tool to predict outcomes of cirrhosis

A new statistical model created from artificial intelligence can more accurately predict cirrhosis outcomes. Image via bcm.edu

Currently, the standard of care for cirrhosis patients is limited because physicians can't accurately predict long-term outcomes. But this might be changing thanks to researchers at Baylor College of Medicine, the Michael E. DeBakey Veteran's Affairs Medical Center, and the Center for Innovations in Quality, Effectiveness and Safety (IQuESt).

According to their study are published in JAMA Network Open, the researchers developed a model using a blend of artificial intelligence and traditional statistical methods to produce a score better predicting mortality in cirrhosis.

"When we see patients in the clinic we want to guide them about their long-term outcomes. We wanted to create a tool using machine learning and artificial intelligence to improve the accuracy of prognosis, while maintaining ease of use in the clinic," says Dr. Fasiha Kanwal, the author of the study and professor of medicine and section chief of gastroenterology at Baylor, in a news release.

The scientists used data collected from patients at 130 hospitals and clinics — such as demographics, comorbidities, underlying risk factors and severity of liver disease — as well as comprehensive laboratory tests and medication data to create three different statistical models to predict risk of mortality.

"Machine learning and artificial intelligence is important. It did help us find the right risk factors to use, but we didn't need to use very complex models to get there. We were able to create the CiMM score that will work easier in the clinic and is more predictive of mortality than the existing method," says Kanwal.

The Cirrhosis Mortality Model (CiMM) performed the best and most accurately and was more predictive than the current prognostic model, known as the Model for End Stage Liver Disease with sodium (MELD-Na).

"This tool could make a big difference in providing patient-centered care. The CiMM score could be reassessed every time a patient comes into the clinic," Kanwal said. "Previously, we were unable to predict anything long term. But the CiMM score could give us an idea of how to manage disease for one, two and three years out."

UTHealth's $11 million grant to study multi-drug resistant infection factors

A local multi-institutional research team has received millions to study drug resistance. Photo via Getty Images

A program at the University of Texas Health Science Center at Houston has received an $11 million grant from the National Institute of Allergy and Infectious Diseases to conduct this five-year study on why some critically ill patients develop multidrug-resistant infections.

The Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients will enroll patients at both Memorial Hermann Hospital-Texas Medical Center and The University of Texas MD Anderson Cancer Center.

According to a news release, the research team will seek to explain the microbial, clinical, and antimicrobial resistance factors of three major multidrug-resistant pathogens: Vancomycin-resistant enterococci, Enterobacterales producing extended spectrum β-lactamases/carbapenemases, and Clostridioides difficile. Note: all three pathogens are resistant to antimicrobial treatment such as antibiotics.

"We want to learn more about how these three classes of organisms colonize the gastrointestinal tract of critically ill patients and, eventually, cause infections in these patient populations," says Dr. Cesar A. Arias, the study's principal investigator and professor of infectious disease at McGovern Medical School at UTHealth.

UTHealth has created a clinic that will provide a myriad of expert physicians for patients still dealing with COVID-19 symptoms. Photo via Getty Images

New clinic in Houston opens to help patients recovering from COVID-19

post-COVID treatment

Houston's first clinic for treatment of patients still coping with symptoms of COVID-19 has opened at UT Physicians, the clinical practice of McGovern Medical School at University of Texas Health Science Center at Houston.

The clinic, part of the new UTHealth COVID-19 Center of Excellence, is staffed by specialists in cardiology, general medicine, neurology, infectious disease, pulmonology, psychiatry, and otorhinolaryngology (ear, nose, and throat). Telehealth and in-person visits are available.

"The UTHealth COVID-19 Center of Excellence brings together our university's experts in adult and pediatric specialty care, public health, biomedical research, and big data analytics — all working to provide the best outcomes for our patients, the best public health and prevention practices for our community, and the best therapies for the virus' short- and long-term impacts," Dr. Giuseppe Colasurdo, president of UTHealth, says in an October 15 release.

Among other things, the COVID-19 Center of Excellence will work on developing reliable testing for the coronavirus, authenticating effective therapies, applying analytics and artificial intelligence to care and research, and collecting virus samples for a "biobank" to study how genetics affects the virus' severity.

Since the emergence of the coronavirus pandemic, scientists and physicians at McGovern Medical School have led clinical trials and treatment protocols, including one of the world's first double-lung transplants for a coronavirus patient. UTHealth is participating in some of the largest national clinical trials to help COVID-19 patients heal, such as studies to prevent progression of the disease and studies seeking proven treatments for critically ill patients.

In one of the country's first randomized clinical trials of its kind, an $8 million grant from the National Institutes of Health is financing a UTHealth study of whether infusions of convalescent plasma can prevent the progression of COVID-19. Another research team is evaluating whether an oral HIF (hypoxia-inducible factor) inhibitor can protect the lungs of COVID-19 patients. The inhibitor is designed to trigger the body's protective response to low oxygen levels.

At the same time, researchers at UTHealth's Cizik School of Nursing are studying the socioeconomic and mental health effects of the virus on Hispanics, while members of the MD Anderson UTHealth Graduate School of Biomedical Sciences are exploring how the time of day a medication is taken might help a COVID-19 patient. In addition, experts at UTHealth's School of Biomedical Informatics are using big data to fight COVID-19.

"Within our six schools, we have the broad expertise that has positioned us as one of the few universities to help our community, Texas and the country through the pandemic and beyond," says Michael Blackburn, executive vice president and chief academic officer of UTHealth. "That starts with amazing clinical care, COVID-19 trials, real-time translational research, and expert knowledge from our public health leaders."

The School of Public Health is leading establishment of a study to be conducted with partners throughout Southeast Texas to assess the virus' long-term consequences, determine factors that contribute to severe outcomes, and enable UTHealth experts to develop and use treatments more effectively. In addition, a community information exchange will be built to connect vulnerable populations with healthcare and social service providers.

"In these unprecedented times, the six schools at UTHealth are rapidly evolving the science and medical care for patients with COVID-19 and our community," says Dr. Bela Patel, vice dean of healthcare quality at McGovern Medical School. "Prevention, new therapeutics, and post-COVID-19 care for our patients with prolonged COVID-19 disease is the mission for the UTHealth Center of Excellence for COVID-19."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

10+ can't-miss Houston business and innovation events for October

where to be

Houston's busy business event season is in full swing, and there are ton of local innovation and entrepreneurship-focused programming across the city. Here's a rundown of what all to throw on your calendar for October when it comes to innovation-related events.

This article will be updated as more business and tech events are announced.

October 4 — Softeq Venture Studio Happy Hour

The Softeq Venture Studio is excited for you to meet the newest startups accepted into its 2H 2022 Cohort. Meet the teams and learn more about how they secured $125K in funding.

You'll have the chance to meet the startup founders, learn about the problems being solved, and learn more about how the Softeq Venture Studio de-risks growing startups.

The event is Tuesday, October 4, at 5 pm, at Yardhouse (City Centre). Click here to register.

October 5 — State of the Airports

Houston Airports is one of North America's largest and busiest multi-airport systems in the world and plays an important role in the greater Houston region's position as a great global city.

State of the Airports features Houston Airports Director, Mario Diaz, who will share the latest information and growth plans for Houston's three airports. Diaz will also address the important role the Houston Airports plays in bolstering Houston's position as an international air gateway.

The event is Wednesday, October 5, 10:30 am to 1:30 pm, at the Marriott Marquis. Click here to register.

October 11 — State of Space

Earlier this month, Space City celebrated the 60th anniversary of President John F. Kennedy’s proclamation delivered at Rice Stadium, "We choose to go to the moon." Many decades ago, these words showed the world that Houston holds a place as the epicenter for the world's biggest space endeavors and while space exploration has changed tremendously since those famous words, Houston's reputation in aviation and aerospace only grows stronger.

Join the Greater Houston Partnership for State of Space on Tuesday, October 11, to hear from some of the sharpest minds in aerospace and aviation technology who continue to chart a vibrant future for Houston centered around NASA's Johnson Space Center and one of the world’s only truly urban commercial spaceports.

Speakers include:

  • Featured speaker and panelist: Vanessa Wyche, Director, NASA’s Johnson Space Center
  • Stephen Altemus, President & CEO, Intuitive Machines
  • Peggy Guirges, General Manager of Space Systems, Collins Aerospace
  • Panel Moderator: Arturo Machuca, Director, Houston Spaceport and Ellington Airport

The event is Tuesday, October 11, 10:30 am to 1:30 pm, at Impact Hub Houston (1801 Main street 10th Floor). Click here to register.

October 12 —  Making an Impact in the Houston Tech Ecosystem

You may have heard that Jay Steinfeld was the founder and CEO of Global Custom Commerce, which operates the world’s top online window coverings retailer Blinds.com. Boot-strapped in 1996 for just $3,000 from his Bellaire garage, Global Custom Commerce was acquired by The Home Depot in 2014. Jay remained its CEO and later joined The Home Depot Online Leadership Team. After stepping away from these roles in early 2020, he has increased his involvement on numerous private company boards and serves as a director of the public company Masonite (NYSE: DOOR). He also teaches entrepreneurship at Rice University’s Jones Graduate School of Business and supports numerous charities. Jay is an Ernst & Young Entrepreneur of the Year and has earned a Lifetime Achievement Award from the Houston Technology Center. Active as an industry speaker on corporate culture, core values, how to scale a start-up, and disruption, he has more than 100 published articles.

But did you know that many of Jay’s former employees have started businesses of their own, formed angel investment funds, developed and led some of Houston’s best technology teams, and grown into pillars of the HouTech community?

Come hear what’s sure to be an intriguing panel discussion with Jay and several ex-Blinds.com’ers as they discuss company culture, core values, lessons learned, and thoughts on the HouTech ecosystem and take questions from the audience.

The event is Wednesday, October 12, at 6 pm, at the Ion. Click here to register.

October 13 — October Transitions on Tap

Transition On Tap is Greentown Labs' monthly networking event devoted to fostering conversations and connections among the climate and energy transition ecosystem in Houston and beyond. Entrepreneurs, investors, students, and friends of climatetech are invited to attend, meet colleagues, discuss solutions, and engage with our growing community. If you’re looking for a job in climatetech or energy, trying to expand your network, or perhaps thinking about starting your own energy-related company, this is the event for you.

The event is Thursday, October 13, 5 to 7 pm, at Greentown Houston. Click here to register.

October 14 — Tech, Tools and Tips: Digital Training Day at Impact Hub Houston

Struggling with a process in your business? There's probably a tech tool for that. Impact Hub Houston invites YOU to attend an extended edition of its Tech, Tools, and Tips Series hosted in partnership with Frost Bank.

The goal for this session is to provide small business owners with an overview of various digital tools that can help your day to day operations. By attending this event, you will learn about various digital tools and also have an opportunity to network with other small business owners.

The event is Friday, October 14, 8:30 am to 12:30 pm, at the Omni Riverway. Click here to register.

October 14-16 — Incubate Galveston + the Ion Hackathon 2022

A hackathon is a social design sprint that brings together the community to work in teams creating innovative solutions. Basically, it’s a party, and a 48-hour race between teams competing to develop solutions to problem-sets for cash prizes. Participants will work in small teams that have a collection of experts, entrepreneurs, students, and community members to tackle the below identified challenges:

  • Increase food access in urban core neighborhoods
  • Create opportunities for green initiatives, including environmental education, coastal resilience, and conservation
  • Propose home refurbishment programs and housing
  • Develop capacity for education and workforce skills development
  • Solve the plastic pollution issue in Galveston: Plastic trash in the water supply, on the beaches, and in the waterways of Galveston and surround areas affects the community in many ways (e.g., beaches look dirty, the plastic has chemicals harmful to health, and microplastics get into the environment and remain there for long periods of time. How can we solve this problem, removing and reducing waste and its downstream impacts, and make our community safer and cleaner? The plastic pollution problem can be address in the way of innovative preventive steps, innovation treatments, and public education, etc.
  • Offer creative solutions to other challenges

The event is Friday, October 14, to Sunday, October 16, at the Marmo Plaza. Click here to register.

October 19 — How to Build an App without Code, Part 1: Info Session (In-Person & Online)

Join Heather Wilson, a UX Researcher, Service Designer and Google Design Sprint Facilitator, as she teaches you how to build an app without code!

Benefits of building an app without code:

  • building a custom app could take months to a year to develop
  • coding could present problems when your mobile strategy is pivoting
  • allows for customization and the ability to make changes as needed
  • high costs can be associated with building am app
The event is Wednesday, October 19, at 6 pm, online. Click here to register.

October 20 — 2022-2023 UH Energy Symposium Series

Rising electricity prices, increasing concerns about grid reliability, and achieving carbon-free electricity in the U.S. by 2035 have refocused attention on the role of nuclear in the energy transition. This comes after a decade of low investments, accumulating nuclear waste, an aging fleet of reactors, public opposition, and regulatory mandates that stalled nuclear’s growth and led to declines in production. Meanwhile, the nuclear industry has maintained its safety record, made remarkable progress in fusion and advanced nuclear reactors, and improved operating safety and efficiency.

The first topic of the 2022-2023 Energy Symposium Series, The Future of Nuclear in the Energy Transition, will address if and how headways in advanced nuclear reactors, fusion, and waste management can overcome the challenges of economic feasibility, efficient and safe waste disposal, and build public and regulatory support for the increased deployment of nuclear energy in the U.S. We are excited to bring our panel discussion of Critical Issues in Energy back on campus this year.

The event is Thursday, October 20, at 6 pm, at Hilton University of Houston - Conrad N. Hilton Ballroom . Click here to register.

October 26-27 — Fuze

Fuze is bringing together the builders and innovators in energy tech. Shutting down 5 blocks in downtown Houston for two days and covering three content tracks, the event is focused on discovering breakthroughs in energy technology.

The event is Wednesday, October 26, to Thursday, October 27, at 8th Wonder Brewery. Click here to register.

October 27 — Aerospace Investment & Engagement

Join the Houston Angel Network as they discuss the current and future state of aerospace innovation and investment, followed by pitches.

The event is Thursday, October 27, at 8 am to 1 pm at the Ion. Click here to register.

October 27 — Space-Related Technology Development and the Houston Innovation Community

In these presentations, Mr. Montgomery Goforth and other aerospace subject matter experts will discuss the technology development challenges faced by NASA’s Johnson Space Center and the surrounding Aerospace community in our ongoing efforts as the hub of human spaceflight. Presentations will focus on the ways in which these challenges, and the associated opportunities, can be leveraged by Houston’s innovation community.

The event is Thursday, October 27, at 4 pm at the Ion. Click here to register.

Houston company names lifetime achievement, finalists for annual energy industry awards

they've got grit

Houston Mayor Sylvester Turner and three energy executives have been named first-time winners of lifetime achievement awards as part of ALLY Energy’s sixth annual GRIT Awards and Best Energy Workplaces program.

ALLY Energy says the honorees have demonstrated “a distinguished career championing change in energy and climate in the private or public sector in the areas of technology, policy, and workforce.”

As mayor of Houston, Turner has led efforts to use renewable energy throughout the city.

The other winners of lifetime achievement awards are:

  • Elizabeth Gerbel, founder and CEO of Houston-based EAG Services and EAG 1Source, which provide consulting services for the energy industry.
  • Lorenzo Simonelli, CEO of Houston-based oilfield services company Baker Hughes.
  • Kevin Sagara, executive vice president and group president of San Diego-based utility company Sempra. He is chairman of Sempra-owned San Diego Gas & Electric Co. and Southern California Gas Co.

The lifetime achievement honorees will be recognized October 26 during an event at The Bell Tower in Houston. So will the winners in the GRIT Awards and Best Energy Workplaces program. The keynote speaker will be U.S. Department of Energy official Shalanda Baker.

“This year’s GRIT Awards and Best Energy Workplaces finalists are a diverse cohort of game-changing entrepreneurs, gritty leaders, collaborative teams, and companies committed to combating climate change. The energy workforce is doing great things to transform our energy ecosystem, and we’re excited to spotlight exceptional talent and culture,” says Katie Mehnert, founder and CEO of Houston-based ALLY Energy, which provides a workforce development platform for the energy industry.

Among the dozens of award finalists are energy-related organizations or their representatives. These organizations include Baker Hughes, ExxonMobil, Halliburton, Marathon Oil, Rice University, Saudi Aramco, Shell, the University of Houston, Syzygy Plasmonics, and Wood Mackenzie.

A complete list of the finalists is available on the ALLY Energy website.